DeutschNewstral
Article
Mmarketwatch.com on 2018-06-27 14:20
Global Blood Therapeutics shares drop after late-stage data for sickle cell disease treatment
Related news
- MGlobal Blood Therapeutics stock up 40% after FDA agrees to accelerated approval pathway for sickle cell disease drugmarketwatch.com
FDA approves new treatment for sickle cell diseasechicagodefender.com
FDA approves gene-editing treatment for sickle cell diseaseDallas News- MGlobal Blood Therapeutics and Syros Pharmaceuticals partner for sickle cell therapiesmarketwatch.com
- MGlobal Blood Therapeutics is making a big gamble on its sickle cell drugmarketwatch.com
Beam Therapeutics Is Aiming To Start Human Trials For Its Sickle Cell TreatmentForbes- MGlobal Blood Therapeutics stock is up on sickle cell therapy approvalmarketwatch.com
- Beam Therapeutics Cofounder And Crispr Scientist Publishes Research On New Sickle Cell Treatment In MiceForbes
FDA Approves First Cell-Based Therapies for Treatment of Sickle Cell Diseasejdsupra.com- The FDA Approves Two New Gene Therapies for the Treatment of Sickle Cell Diseasejdsupra.com
‘Remarkable’ gene-editing treatment for sickle cell disease is approved by FDAFox News
FDA approves first CRISPR gene editing treatment that may cure sickle cell diseaseSan Jose Mercury News
FDA approves new drug for sickle cell diseasenews5cleveland.com- DFDA approves CRISPR gene therapy trials for sickle cell diseasedailycal.org
- Sickle Cell Disease Getting the Support it Needs.chicagodefender.com
- TWhat’s wrong with the cure for sickle cell disease?thereflector.ca
A new cure for sickle cell disease may be comingrssfeeds.king5.com
Two gene therapies for sickle cell disease approved in USSeattle Times- MSickle Cell Disease Getting the Support it Needsmichiganchronicle.com